Generic drug companies in particular are guilty of a lot of misinformation. Having listened with an open mind to what officials told us yesterday, I understand that the aim of this bill is not to bring in changes, but rather to restore the situation that prevailed in 2006. With the freezing of the patent register, innovative pharmaceutical companies agreed to allow themselves to be controlled and kept in line. In its ruling, the Supreme Court did not speak out about the criteria.
The timeframe does not seem that draconian to me, since we're reverting to the situation that existed in 2006, when consultations took place over a period of one year. It is now time for us to forge ahead. If we start examining this matter all over again and call for additional delays, we will never see the end of it and industry stakeholders will never manage to agree.
Therefore, we oppose this motion.